Brief: Sensorion Surpasses Enrollment Target For SENS-401 In SSNHL

Sensorion SA

27/10/2021 06:34

Oct 27 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION SURPASSES ENROLLMENT TARGET FOR SENS-401 IN
SSNHL,
RESULTS AVAILABLE IN JANUARY 2022
    * SENS-401 IS ALSO PROGRESSING IN OTHER INDICATIONS.
    * IMMINENT COMPLETION OF AUDIBLE-S TRIAL IN SSNHL FOLLOWS
ACCEPTANCE BY REGULATORY AUTHORITIES OF AN AMENDMENT TO
STATISTICAL ANALYSIS PLAN FOR STUDY ANNOUNCED WITH SENSORION'S
H1 RESULTS ON SEPTEMBER 27TH, 2021
    * SENSORION WILL ALSO SUBMIT A CLINICAL TRIAL APPLICATION
FOR A
PHASE 2 STUDY OF SENS-401 CLINICAL STUDY IN CISPLATIN-INDUCED
OTOTOXICITY (CIO) IN Q4 2021
    * SENSORION AND ITS PARTNER COCHLEAR LIMITED, WILL SUBMIT A
CLINICAL TRIAL APPLICATION FOR SENS-401 IN PATIENTS SCHEDULED
FOR COCHLEAR IMPLANTATION BEFORE YEAR END
    * AUDIBLE-S IS AN IMPORTANT PART OF DEVELOPMENT OF SENS-401
AS A
PIPELINE ASSET FOR SENSORION AND WE ARE LOOKING FORWARD TO
SHARING TOP LINE RESULTS OF STUDY IN JANUARY 2022-CMO

Source text for Eikon:  ID:nBw228qyxa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))